In Alzheimer’s disease, the accumulation of amyloid β in the brain begins approximately 20 years before diagnosis, and damage to neural circuits progresses. We have conducted our research based on the belief that “preventing and repairing the breakdown of neural networks is critically important for maintaining and restoring cognitive function.”
Diosgenin is known as a component of the herbal medicine yam (the rhizome of Dioscorea japonica or D. batatas). First, we discovered that diosgenin reverses the atrophy of axons and dendrites induced by amyloid-β in cultured nerve cells. Furthermore, oral administration of diosgenin to Alzheimer’s disease model mice after the onset of memory impairment restored their memory capacity. Furthermore, we identified SPARC and Galectin-1 as the molecules responsible for the subsequent increase in axonal repair, respectively, and elucidated the mechanism by which the increase in these molecules enables axons to regrow in the correct direction.
To conduct clinical studies, we utilized the food-drug classification and used a high-concentration diosgenin-containing yam extract as the test drug. After confirming in mice that the diosgenin-rich yam extract has memory-enhancing and improving effects, we conducted a randomized, double-blind, crossover study in healthy adults and demonstrated that 12 weeks of administration of the yam extract significantly improved cognitive function compared to the placebo group. Furthermore, we conducted specific clinical studies in patients with mild cognitive impairment and mild Alzheimer’s-type dementia and confirmed the cognitive-enhancing effects of 24 weeks of extract administration.
We have recently discovered that diosgenin is also effective in restoring visual field defects caused by glaucoma and are currently advancing this finding into clinical research.
As our society continues to age, interest is growing not only in the treatment of diseases but also in its prevention. Clinical evidence is essential for advancing drug development; at the same time, it serves to verify whether the targets of basic research are valid. Considering the current regulatory landscape regarding the food-drug classification and the approval regulations for natural product-based pharmaceuticals, we are moving forward with societal implementation while keeping multiple potential outcomes in mind.